[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100643569":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":32,"centralContacts":36,"locations":41,"responsibleParty":55,"collaborators":31,"id":58,"slug":31,"hasResults":59,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":31,"eligibilityCriteria":63,"healthyVolunteers":59,"sex":64,"minAge":65,"maxAge":66,"enrollmentInfo":67,"targetDuration":31,"studyType":70,"phases":71,"briefSummary":73,"conditions":74,"keywords":77,"overallStatus":44,"whyStopped":31,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":91},{"fullName":5,"class":6},"Horus University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Desloratadine Group","EXPERIMENTAL","Participants will receive desloratadine 5mg in addition to standard disease modifying antirheumatic drug therapy.",[13],"Drug: Desloratadine 5 mg",{"label":15,"type":10,"description":16,"interventionNames":17},"Placebo Group","Participants will receive placebo in addition to standard disease modifying antirheumatic drug therapy.",[18],"Drug: Placebo",[20,27],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Desloratadine 5 mg","Desloratadine administered orally as add on therapy to standard disease modifying antirheumatic drugs.",[9],[26],"Desloratadine",{"type":21,"name":28,"description":29,"armGroupLabels":30,"otherNames":31},"Placebo","Matching placebo administered orally as add on therapy to standard disease modifying antirheumatic drugs.",[15],null,[33],{"name":34,"affiliation":5,"role":35},"Amira Mashaly","PRINCIPAL_INVESTIGATOR",[37],{"name":34,"role":38,"phone":39,"phoneExt":31,"email":40},"CONTACT","01028275001","amashaly@horus.edu.eg",[42],{"facility":43,"status":44,"city":45,"state":31,"zip":31,"country":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"Faculty of medicine, Mansoura University","RECRUITING","Al Mansurah","Egypt",{"type":48,"coordinates":49},"Point",[50,51],31.38069,31.03637,{"lat":51,"lon":50},[54],{"name":34,"role":38,"phone":39,"phoneExt":31,"email":40},{"type":35,"investigatorFullName":56,"investigatorTitle":57,"investigatorAffiliation":5,"oldNameTitle":31,"oldOrganization":31},"Amira Fawzy Mohamed Mashaly","Principal Investigator","100643569",false,"NCT07632872","Desloratadine as Adjunct Therapy for Rheumatoid Arthritis","Effect of Desloratadine as Add-On Therapy in Rheumatoid Arthritis","Inclusion Criteria:\n\n* Patients with active rheumatoid arthritis according to the 2010 American College of Rheumatology and European League Against Rheumatism classification criteria.\n* Disease Activity Score in 28 joints (DAS28) greater than 2.6.\n* Age between 18 and 60 years.\n* Male and female patients.\n* Patients receiving methotrexate in addition to standard conventional therapy.\n* Ability to provide written informed consent.\n\nExclusion Criteria:\n\n* Patients with renal or hepatic disease.\n* Known hypersensitivity to the study medications.\n* Current use of antioxidant supplements.\n* History of psychiatric disorders.\n* Use of oral prednisolone at a dose greater than 15 mg per day.\n* Current treatment with biological disease modifying antirheumatic drugs.\n* Pregnant or breastfeeding patients.\n* History of cardiac arrhythmias or prolonged QT interval.\n* Use of medications known to prolong the QT interval.","ALL","18 Years","60 Years",{"count":68,"type":69},60,"ESTIMATED","INTERVENTIONAL",[72],"PHASE2","Rheumatoid arthritis is a chronic inflammatory disease that causes joint pain, swelling, and reduced physical function. Although standard disease-modifying antirheumatic drugs are effective for many patients, some individuals continue to have active disease.\n\nThe purpose of this study is to evaluate the effectiveness and safety of adding desloratadine to standard therapy in patients with active rheumatoid arthritis. Participants will receive either desloratadine or placebo in addition to their usual treatment.\n\nThe study will assess changes in disease activity and inflammatory markers over a follow-up period of approximately 12 weeks. The results of this study may help determine whether desloratadine could be a useful add-on treatment option for patients with rheumatoid arthritis.",[75,76],"Rheumatoid Arthritis (RA)","Rheumatoid Arthritis",[26,78,79,80,81],"Rheumatoid arthritis","Add-on therapy","Inflammation","Randomized controlled trial","2026-06-02",{"date":84,"type":85},"2026-06-08","ACTUAL",{"date":87,"type":85},"2026-05-23",{"date":89,"type":69},"2027-01",{"name":5,"class":6},1]